Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung

Bile Duct Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Non-Small Cell Lung Cancer Metastatic

Gallbladder Cancer Unresectable

Carcinoma, Hepatocellular

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms, Small Cell Lung Carcinoma

Cholangiocarcinoma

Pathologic Complete Response, Breast Neoplasms, Hemangiosarcoma, Neoplasms, Triple Negative Breast Neoplasms

Fibrosis, Carcinoma, Hepatocellular, Hypertension, Portal

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Carcinoma, Hepatocellular, Liver Neoplasms

Carcinoma, Non-Small-Cell Lung, Respiratory Tract Neoplasms

Biliary Tract Neoplasms, Carcinoma, Hepatocellular

Small Cell Lung Carcinoma

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Neoplasm Metastasis, Pancreatic Neoplasms, Endometrial Neoplasms

Small Cell Lung Carcinoma

Lung Neoplasms, Small Cell Lung Carcinoma

Bile Duct Neoplasms, Cholangiocarcinoma

Limited Stage Small Cell Lung Cancer

Breast Neoplasms

Liver Neoplasms

Pancreatic Neoplasms

Hemangiosarcoma, Liposarcoma, Osteosarcoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Gastric Adenocarcinoma

Non-Muscle Invasive Bladder Neoplasms

Carcinoma, Hepatocellular

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Node; Prostate

Platinum-Resistant Lung Small Cell Carcinoma

Carcinoma, Non-Small-Cell Lung

Advanced Biliary Tract Carcinoma

Hepato Cellular Carcinoma

Leukemia, Lymphocytic, Chronic, B-Cell

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Cholangiocarcinoma

Urinary Bladder Neoplasms

Colorectal Neoplasms

Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

Lung Neoplasms

Clinical Trials

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Ablatio

DIAMOND

REVIVE

STAGGER

GCND

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer

Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy

Low-dose Radiotherapy Combined With Durvalumab, Chemotherapy(EP) in the Treatment of ES-SCLC

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement

I-SPY

Durvalumab (MEDI4736) and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant

SPRINT 2

Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC

IOSPHERE

Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer

MIGRANT

Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer

MOZART

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

DUMELEP

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

DURVALUNG

Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio

TIGOS-LS

DTP

A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinoma

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

DOSa

Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial

Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma

ENHANCE

Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma

358

Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)

POSTCARD

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

TRADE-hypo

TACTIC

IIT2025-03-YANG-LIFT-HCC

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma

TRIFECTA

Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)

DUTHY

REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)